|
Bioniche, Endo Halt Phase III Trial of Bladder Cancer Drug
Bioniche and Endo Pharmaceuticals are halting their Phase III trial of non-muscle-invasive bladder cancer treatment Urocidin because the trial failed to recruit subjects at the expected rate.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives